Company News

Radius Health Inc (NASDAQ:RDUS) announced that it has completed its $43 million equity financing, which will be used to support the advancement of the company’s lead asset, BA058, a bone-building compound that will treat patients with osteoporosis.

Radius Health Inc (NASDAQ:RDUS) announced that it has completed its $43 million equity financing, which will be used to support the advancement of the company’s lead asset, BA058, a bone-building compound that will treat patients with osteoporosis.

As quoted in the press release:

Mr. Wyzga continued, “Our recently reported interim blinded safety data for clinical fractures occurring in the Phase 3 trial and the completion of enrollment in both the subcutaneous Phase 3 and the short-wear time patch Phase 2 trials demonstrate solid progress toward our goal of commercializing this compound. Osteoporosis is a large market. Currently available treatments do not adequately serve the needs of patients, especially those at high risk of fracture.

Click here to read the full Radius Health Inc (NASDAQ:RDUS) press release.

Featured

MARKETS

Markets
TSX20532.18+148.43
TSXV714.66+12.92
DOW32637.19+516.91
S&P 5004057.84+79.11
NASD11740.65+305.91
ASX7105.90-49.30

COMMODITIES

Commodities
Gold1861.24+8.18
Silver22.37+0.34
Copper4.29+0.03
Palladium2042.00+34.00
Platinum959.00+10.00
Oil113.02-1.07
Heating Oil3.81-0.04
Natural Gas8.53-0.36

DOWNLOAD FREE REPORTS

×